N-(4-chlorophenyl)-5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine | 35213-10-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-chlorophenyl)-5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine
• 英文别名: 2-(4-chlorophenyl)amino-5-(4-pyridyl)-1,3,4-thiadiazole；(4-chloro-phenyl)-([4]pyridyl-[1,3,4]thiadiazol-2-yl)-amine；(4-Chlor-phenyl)-([4]pyridyl-[1,3,4]thiadiazol-2-yl)-amin；N-(4-chlorophenyl)-5-(4-pyridinyl)-1,3,4-thiadiazol-2-amine；N-(4-chlorophenyl)-5-pyridin-4-yl-1,3,4-thiadiazol-2-amine
• CAS: 35213-10-6
• 化学式: C₁₃H₉ClN₄S
• 分子量: 288.76
• InChiKey: FFPDTGFPPGPYKH-UHFFFAOYSA-N

物化性质

• 熔点：
  238-240 °C(Solv: ethanol (64-17-5))
• 沸点：
  476.1±55.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(4-chlorophenyl)-2-(pyridin-4-ylcarbonyl)hydrazinecarbothioamide 在 硫酸 作用下， 以 水 为溶剂， 以78%的产率得到N-(4-chlorophenyl)-5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine
  参考文献：
  名称：

  Yar, Mohammad Shahar; Akhter, Mohammad Wasim, Acta poloniae pharmaceutica, 2009, vol. 66, # 4, p. 393 - 397

  摘要：

  DOI：

文献信息

• Synthesis and Anticancer Evaluation of 1,3,4-Oxadiazoles, 1,3,4-Thiadiazoles, 1,2,4-Triazoles and Mannich Bases
  作者：Nadia Youssef Megally Abdo、Mona Monir Kamel

  DOI：10.1248/cpb.c15-00059

  日期：——

  A series of 5-(pyridin-4-yl)-N-substituted-1,3,4-oxadiazol-2-amines (3a-d), 5-(pyridin-4-yl)-N-substituted-1,3,4-thiadiazol-2-amines (4a-d) and 5-(pyridin-4-yl)-4-substituted-1,2,4-triazole-3-thiones (5a-d) were obtained by the cyclization of hydrazinecarbothioamide derivatives 2a-d derived from isonicotinic acid hydrazide. Aminoalkylation of compounds 5a-d with formaldehyde and various secondary amines

  一系列5-（吡啶-4-基）-N-取代的1,3,4-恶二唑-2-胺（3a-d），5-（吡啶-4-基）-N-取代的1，通过环化获得3,4-噻二唑-2-胺（4a-d）和5-（吡啶-4-基）-4-取代的1,2,4-三唑-3-硫酮（5a-d）异烟酸酰肼衍生的肼基碳硫代酰胺衍生物2a-d。用甲醛和各种仲胺将化合物5a-d进行氨基烷基化，得到曼尼希碱6a-p。根据它们的光谱数据和元素分析确定了新合成化合物的结构。筛选所有化合物针对六种人类癌细胞系和正常成纤维细胞的体外抗癌活性。测试的化合物中有十六种对大多数细胞系表现出明显的细胞毒性。在这些衍生物中，曼尼希（Mannich）碱基6j 发现6m和6p表现出最有效的活性。与标准CHS 828（IC50 = 0.025 microM）相比，Mannich base 6m对胃癌NUGC（IC50 = 0.021 microM）表现出更强的细胞毒活性。正常成纤维细
• 1,3,4-Thiadiazole Derivatives. Synthesis, Structure Elucidation, and Structure−Antituberculosis Activity Relationship Investigation
  作者：Elçin E. Oruç、Sevim Rollas、Fatma Kandemirli、Nathaly Shvets、Anatholy S. Dimoglo

  DOI：10.1021/jm0495632

  日期：2004.12.1

  A series of 2,5-disubstituted-1,3,4-thiadiazoles were synthesized, the compounds structures were elucidated and screened for the antituberculosis activity against Mycobacterium tuberculosis H37Rv using the BACTEC 460 radiometric system. Among the tested compounds, 2-phenylamino-5-(4-fluorophenyl)-1,3,4-thiadiazole 22 showed the highest inhibitory activity. The relationships between the structures of compounds and their antituberculosis activity were investigated by the Electronic-Topological Method (ETM) and feed forward neural networks (FFNNs) trained with the back-propagation algorithm. As a result of the approach, a system of pharmacophores and anti-pharmacophores has been found that effectively separates compounds of the examination set into groups of active and inactive compounds. The system can be applied to the screening and design of new active compounds possessing skeletons similar to those used in the present study.
• ZHANG, ZIYI;YANG, KEXIN;ZENG, FULI, CHEM. J. CHIN. UNIV., 9,(1988) N 3, 239-245
  作者：ZHANG, ZIYI、YANG, KEXIN、ZENG, FULI

  DOI：——

  日期：——
• ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：Magenta Therapeutics Inc.

  公开号：US20210220408A1

  公开（公告）日：2021-07-22

  The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.